Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept

Changes in serum cartilage oligomeric matrix protein (COMP) were studied during a 6-month period from initiation of treatment of rheumatoid arthritis patients with either infliximab or etanercept, to elucidate whether the favourable results of tissue protection reported in clinical trials are corrob...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Arthritis Res Ther
Principais autores:	Crnkic, Meliha, Månsson, Bengt, Larsson, Lotta, Geborek, Pierre, Heinegård, Dick, Saxne, Tore
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2003
Assuntos:	Research Article
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC165057/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12823852/ https://ncbi.nlm.nih.govhttps://doi.org/10.1186/ar760
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!